Board summary
Key figures
59,554
Registered population
62.6% aged 18–64
16.8%
Aged 65+
ICB 14.9% · England 17.9%
43.3%
In IMD quintile 1
ICB 40.7% · England 21.0%
~22,111
Core20 residents (est.)
Resident basis; registered basis ~25,697 · see page 3
9,666
Hypertension register
+5.27% in 3 yrs · England +5.60%
650
SMI register
19.5% of Stockport (LAD)'s
1,919
COPD register
Reviews -9.77% in 3 yrs
Forecast to 2030
10,986
Hypertension patients, 2030
+1,320 on today
75.4%
QRISK ≥20% on statins, 2030
+2.46pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews fall behind national trends.
Coverage is 61.2% (England 65.7%) after a -9.1% three-year change (England +4.4%), leaving about 1,500 unreviewed patients, which could reflect recall limits.
Pre-school booster coverage trails the 95.0% target.
Age-5 4-in-1 booster uptake is 86.7% (8.3 pp below the 95.0% target) and MMR dose 2 is 92.1%, which may indicate recall gaps.
Hypertension blood pressure control exceeds national averages.
Control reaches 70.0% in patients under 80 (England 67.8%, ICB 68.6%) and 84.5% in those aged 80+ (England 81.2%, Stockport 83.8%).
Population, age and ethnicity
Older adults make up 16.8% of registered patients, below Stockport's 19.7% comparator
Across 59,554 registered patients, 16.8% (10,009 patients) are aged 65+, below Stockport (19.7%), above NHS Greater Manchester ICB (14.9%), and below England (17.9%). Children aged 0–17 make up 20.6% (12,240 patients; Stockport 19.7%, ICB 21.8%, England 19.6%). Census estimates record Gypsy or Irish Traveller residents at 0.1% and Roma at 0.1%. Catchment care homes total 14 with 562 beds, including 6 associated with Alvanley Family Practice and 5 with Brinnington Surgery. List size is projected to grow 1.2% to 2030 (Stockport 1.1%, ICB 1.6%, England 2.3%) under an unverified methodology.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Stockport LA) | 2,072 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Stockport LA) | 919 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Stockport LA) | 23.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients make up 43.3% of the PCN list, above Stockport and England
Core20 patients make up 43.3% of the PCN list, above Stockport (16.1%), NHS Greater Manchester Integrated Care Board (40.7%), and England (21.0%). Across captured practices, Woodley Village Surgery records a Core20 cohort share of 15.0%. Brinnington Surgery records a Core20 cohort share of 92.4% (8,712 estimated patients). Heaton Norris Medical Practice records a Core20 cohort share of 51.0% (5,397 estimated patients). Family Surgery records a Core20 cohort share of 29.1% (3,305 estimated patients). Resident Core20 estimates (22,111) and practice registered estimates rest on different bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
650
SMI register
1.09% recorded prevalence
392
Learning disability register
0.66% recorded prevalence
14
Care homes, 562 beds
In the PCN catchment
9.5%
Provide unpaid care
Stockport (LAD), Census 2021
Recorded severe mental illness includes 650 patients (1.1%; Stockport 1.0%, ICB 1.1%, England 1.0%) and learning disabilities 392 patients (0.7%; Stockport 0.6%, ICB 0.6%, England 0.6%). Borough rough sleeping was 48 in 2025 and unpaid care was 9.5% in 2021; borough-level figures capture wider local authority context and do not establish PCN list counts.
Severe mental illness: physical health checks
SMI prevalence is 1.1% (650 patients). Recorded checks reached 83.9% for blood pressure (Stockport 85.0%, England 83.4%) and 82.0% for BMI (Stockport 84.0%, England 82.1%), meaning routine monitoring trails borough levels while unrecorded elements cannot imply completed full checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,666
Hypertension register
+5.27%
Register growth, 3 yrs
Stockport (LAD) +4.99% · England +5.60%
+2.93pp
BP control, under 80
≤140/90 · +3.17pp aged 80+
+1,320
More patients by 2030
Forecast 10,986 (18.03%)
Hypertension case-finding and control
Recorded hypertension prevalence is 16.3% (9,666 patients), above England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%), and in line with Stockport (16.2%). Recent blood pressure checks reach 90.3% (England 90.0%, Stockport 91.2%). Blood pressure control exceeds national averages: 70.0% aged under 80 achieve <= 140/90 mmHg (England 67.8%, Stockport 70.8%) after a +4.4% three-year rise (England +3.2%), and 84.5% aged 80+ are controlled (England 81.2%). Conversely, annual reviews across 796 heart failure patients fell 9.6% over 2023 to 2025 (England +8.7%) to 73.7%, trailing England (78.5%) and Stockport (79.3%). While hypertension control outperforms England, trailing heart failure reviews could reflect recall capacity limits, testable by auditing appointments.
Lipids and statins
Lipid-lowering therapy reaches 70.2% for patients with QRISK >= 20%, exceeding England (63.6%), Stockport (64.8%), and NHS Greater Manchester Integrated Care Board (67.0%). Treatment in chronic kidney disease is 77.7% (England 70.3%). Higher therapy coverage than England is consistent with effective prevention, indicating the PCN should prioritise sustaining treatment pathways across all practices.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 130,439 | £1.70 | £1.94 | £1.86 | £221,746 |
| Cardiovascular (all), 2025 | 178,585 | £3.06 | £3.15 | £3.33 | £546,470 |
In 2026, the PCN prescribed 130,439 lipid-regulating drug items at £1.70 per item, below England (£1.86), NHS Greater Manchester Integrated Care Board (£1.94), and Stockport (£1.99), spending £20,870 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−9.14%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.14%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 3.2% (1,919 patients; Stockport 2.1%), after register growth of +10.1% over 2023 to 2025 (England +2.6%). Over that period, COPD reviews fell 9.8% (England +2.8%) to 68.4% (Stockport 76.4%, England 76.4%). Asthma reviews fell 9.1% (England +4.4%) to 61.2% (Stockport 63.4%, England 65.7%), leaving about 1,500 of 3,935 patients unreviewed. Youth asthma prescribing reached 2,177 per 1,000 aged 5-19 (Stockport 1,720, England 1,488). Falling review coverage could reflect appointment recall bottlenecks, testable by auditing appointments.
Cancer register and children's immunisation
The cancer register records 2,200 patients (3.7%; England 3.8%, Stockport 4.4%). In Q1 2025/26 childhood immunisations, age-5 MMR dose 1 achieved 97.0%, while dose 2 reached 92.1% (4.9 pp lower; 2.9 pp below the 95.0% target). The 4-in-1 booster reached 86.7% (8.3 pp below the 95.0% target; England 80.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of staged cancers were diagnosed at stage 1 or 2 (England 55.3%), showing a distance of -19.4 pp to the 75.0% national ambition by 2028, with 70.8% known staging; reaching 75.0% would require about 2,270 additional early-stage diagnoses annually across the ICB. Within Tame Valley PCN, recorded cancer prevalence is 3.7% (2,200 patients). Breast screening coverage is 63.2% (Stockport 72.6%, England 69.9%). Cervical screening among women aged 25 to 49 is 73.0% (Stockport 75.9%), with a 3-year percentage change of -1.9%. These ICB figures reflect wider system staging rather than PCN performance. Lower breast screening coverage compared to England and Stockport, alongside.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For Stockport NHS Foundation Trust, 62-day referral to treatment performance is 74.6666%, trailing the 85.0% operational standard by 10.3 pp, while NHS Greater Manchester Integrated Care Board stands at 75.7262% (9.3 pp below standard). Faster diagnosis standards are met: Stockport NHS Foundation Trust achieved 83.2086% on the 28-day standard (8.2 pp above the 75.0% standard; ICB 79.5261%), and 97.3913% on the 31-day combined treatment standard (1.4 pp above the 96.0% standard; ICB 96.4937%). Hospital wait standards describe acute trust pathways rather than PCN performance. Diagnostic bottlenecks at trust level mean primary care must maintain rapid referral quality for suspected cancers.
| Pathways within standard (%) | Stockport | Manchester | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 83.21 | 80.06 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 97.39 | 92.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 74.67 | 72.85 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Stockport | Manchester | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 1.41 | 11.68 | 0.00 | 21.40 |
| CT | 2.93 | 14.66 | 0.18 | 9.92 |
| Echocardiography | 17.46 | 4.91 | 0.00 | 28.48 |
| Colonoscopy | 5.53 | 4.51 | 1.51 | 30.83 |
| Gastroscopy | 5.31 | 29.35 | 5.45 | 29.02 |
| All 15 DM01 tests | 14.08 | 8.98 | 0.80 | 23.14 |
| Community services activity | Stockport residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 57,085 | 573,310 |
| Referrals | 10,690 | 94,470 |
| Patients with a contact | 16,950 | 183,535 |
Community services (residents of Stockport), Jun 2026 (provisional). Community service activity recorded across Stockport borough shows that adults aged 65 and over account for 60.6% of all resident contacts, representing 34,585 of the 57,085 total community contacts. These borough-level figures capture resident community service activity rather than individual PCN practice activity. High community contact concentration among older residents highlights the necessity of close coordination between PCN primary care teams and community services.
Practice variation and patient experience
Phone access spans 51.7 percentage points across practices despite high overall QOF achievement
Overall 2025/26 QOF achievement ranges from 90.6% at Brinnington Surgery to 98.2% at Vernon Park Surgery. However, vaccination and immunisation domain achievement spans 61.3 pp, from 24.9% at Alvanley Family Practice to 86.2% at Vernon Park Surgery (England 55.2%). High overall achievement may mask substantial inter-practice variation in routine immunisation delivery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Bredbury | 117 | 24.9 | 94.9% | 83.2% | 93.8% |
| Vernon Park | 106 | 51.3 | 96.7% | 73.7% | 92.3% |
| Heaton Norris | 108 | 51.0 | 64.7% | 70.5% | 87.4% |
| Brinnington | 104 | 92.4 | 93.1% | 80.0% | 86.3% |
| Family Surgery | 108 | 29.1 | 44.9% | 49.4% | 81.6% |
| Alvanley | 95 | 22.6 | 71.7% | 69.1% | 81.5% |
| Woodley Village | 105 | 15.0 | 92.9% | 67.4% | 79.5% |
| Park View | 105 | 32.6 | 70.7% | 76.1% | 75.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 measures trail England over three years, led by falling review rates
Across 25 compared measures, 16 trail England on three-year change. Annual reviews saw the widest relative declines over 2023 to 2025: heart failure reviews fell 9.6% (England +8.7%), COPD reviews fell 9.8% (England +2.8%), and asthma reviews fell 9.1% (England +4.4%). Learning disability registers also contracted by 6.0% (England +5.4%) and stroke fell 0.3% (England +2.3%). By contrast, three-year relative gains exceeded England in breast screening (+10.2% vs England +8.4%) and blood pressure control under age 80 (+4.4% vs England +3.2%). Falling review rates could reflect recall capacity constraints rather than lower need, testable through.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD reviews
Learning disability register
Diabetes HbA1c control
Breast screening (53-70)
BP control, 80+
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Stockport (LAD) | Asset | PCN | Stockport (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (562 beds) | n/a | Schools (catchment) | 86 | n/a |
| Children's centres | 1 | 2 | Places of worship | 38 | 135 |
| Libraries | 5 | 12 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | 1 | no data | Primary schools (LA maintained) | 12 | 61 |
| Primary academies | 13 | 23 | Special schools | n/a | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Asthma review coverage is 61.2% (Stockport 63.4%, England 65.7%) after a -9.1% change over 2023 to 2025 (England +4.4%), leaving 1,525 (about 1,500) of 3,935 patients unreviewed alongside 2,177 youth asthma items per 1,000 (England 1,488). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school booster and MMR2 catch-up
In Q1 2025/26 across 165 five-year-olds, 4-in-1 booster coverage is 86.7% (below the 95.0% target by 8.3 pp; England 80.9%) and MMR dose 2 is 92.1% (4.9 pp below MMR dose 1 at 97.0%). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Combined COPD and heart failure recall
Over 2023 to 2025, COPD reviews across 1,919 patients (3.2%) fell 9.8% (England +2.8%) to 68.4% (England and Stockport 76.4%), and heart failure reviews across 796 patients (1.3%) fell 9.6% (England +8.7%) to 73.7% (England 78.5%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home primary care alignment (p2) | Count of Care Homes in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Heart failure annual review recall (p5) | Heart failure register | — | PCN |
| Pre-school booster and MMR recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage capacity review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school booster and MMR2 catch-up (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Combined COPD and heart failure recall (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
